Pulmonary Nodule: Size, Type, and When You Need Follow-Up

A pulmonary nodule — a small rounded area of increased density in the lung measuring up to 3 cm — is one of the most common incidental findings on chest CT. In lung cancer screening trials, nodules were detected in up to a quarter of participants; the vast majority proved benign. The challenge in general practice is identifying the small subset that represent early-stage lung cancer at a point where treatment is most effective.

A. Core clinical — the AU general-practice framework

Definition and morphology

A pulmonary nodule is a rounded opacity up to 3 cm in its greatest dimension. Opacities larger than 3 cm are called lung masses and require expedited specialist referral regardless of other features.

Nodules are classified by CT appearance:

• Solid — fully opaque, obscures the underlying vasculature
• Sub-solid — two subtypes:
  • Pure ground-glass nodule (GGN) — hazy but pulmonary vessels remain visible through it
  • Part-solid nodule — a denser solid core surrounded by a ground-glass halo

This morphological distinction matters greatly: part-solid > pure GGN > solid for malignancy probability per millimetre of size.

Common benign causes

The differential for a pulmonary nodule is broad and mostly benign:

• Healed granulomatous infections (mycobacterial, fungal — less common in Australia than North America)
• Reactive intrapulmonary lymph nodes (very common, often <5 mm, well-defined oval)
• Pulmonary hamartoma (benign cartilaginous tumour, often with popcorn calcification)
• Focal scar from previous pneumonia or trauma
• Carcinoid tumour (slow-growing, low malignant potential)
• Arteriovenous malformation

Calcification patterns that indicate benign aetiology: central, diffuse, laminated (layered), and popcorn. Eccentric or amorphous calcification does not exclude malignancy.

Risk factors for malignancy

Features that increase the pre-test probability of a malignant nodule:

• Larger size (the strongest single predictor)
• Part-solid or spiculated morphology
• Upper-lobe location
• Current or ex-heavy-smoker (≥20 pack-years)
• Age ≥50 years
• Personal history of lung cancer or another primary malignancy
• Family history of lung cancer in a first-degree relative
• Occupational asbestos, radon, or silica exposure

B. Evidence base — Fleischner 2017 and screening trials

Fleischner Society 2017 guidelines

The Fleischner Society 2017 guidelines are the international standard for managing incidentally detected pulmonary nodules and are followed in Australian practice. Management is stratified by nodule type, size, and individual risk profile.

Solid nodules — single:

Size	Low risk	High risk
< 6 mm	No routine follow-up	Optional CT at 12 months
6–8 mm	CT at 6–12 months, then 18–24 months if stable	CT at 6–12 months, then 18–24 months
> 8 mm	CT at 3 months, PET-CT, or tissue sampling	CT at 3 months, PET-CT, or tissue sampling

Sub-solid nodules — single:

Type	Size	Recommended approach
Pure GGN	< 6 mm	No follow-up required
Pure GGN	≥ 6 mm	CT 6–12 months to confirm persistence; then every 2 years to 5 years
Part-solid	< 6 mm	No follow-up required
Part-solid	≥ 6 mm	CT 3–6 months; if persistent, annual CT for 5 years
Part-solid with growing solid component	Any	Specialist referral

Fleischner exclusions — these guidelines do NOT apply to:

• Persons under 35 years of age
• Patients with known malignancy (assume metastasis until proven otherwise)
• Immunocompromised patients (different differential, different urgency)
• Nodules detected through the Australian Lung Cancer Screening Programme (use Lung-RADS instead)

Screening trial evidence

The National Lung Screening Trial (NLST, NEJM 2011) randomised over 53,000 high-risk smokers to annual LDCT versus chest radiograph for three years and showed a 20% relative reduction in lung cancer mortality in the LDCT arm. The European NELSON trial (NEJM 2020) confirmed a 24% mortality reduction in men and 33% in women at 10 years of follow-up. These trials underpinned Australia’s decision to establish a national screening programme.

C. Australian Lung Cancer Screening Programme

Eligibility criteria (all three required)

• Age 50–70 years
• Smoking history ≥30 pack-years (one pack-year = 20 cigarettes/day for one year; e.g. 1½ packs/day for 20 years = 30 pack-years)
• Currently smoking OR having quit within the last 15 years

Eligible people should be offered a GP referral to an LCSP participating centre. The programme is Medicare-funded for eligible participants and provides annual LDCT.

Lung-RADS versus Fleischner

Screen-detected nodules use the Lung Imaging Reporting and Data System (Lung-RADS), not Fleischner. Lung-RADS categories:

• 1 — negative (no nodules or definitely benign): annual screening
• 2 — benign appearance: annual screening
• 3 — probably benign: 6-month LDCT
• 4A — suspicious: 3-month LDCT or PET-CT
• 4B — very suspicious: tissue sampling or PET-CT
• 4X — highly suspicious with additional malignant features: tissue sampling

The radiology report will state which system was used. If a Fleischner report and an LCSP enrolment overlap, follow the LCSP radiologist’s Lung-RADS recommendation rather than Fleischner.

Harms of screening

False positives are common — most nodules detected in screening are benign. Harms include procedural complications from biopsy (pneumothorax in up to 15% of CT-guided biopsies) and psychological burden of surveillance. Overdiagnosis (detection of cancers too slow-growing to cause death) is an acknowledged limitation. The mortality benefit substantially outweighs these harms in the high-risk population defined by LCSP eligibility criteria.

The Lung Foundation Australia and TSANZ provide patient and clinician resources on the LCSP. RANZCR sets reporting standards for participating LDCT centres.

D. Australian operations

Relevant MBS items

• MBS 57528 — CT thorax (Medicare rebate when clinically indicated for nodule follow-up)
• MBS 61518 — PET scan (rebatable when a solid lesion ≥8 mm or part-solid nodule with growing component requires characterisation)
• MBS 57340 — CT-guided core biopsy of a lung lesion
• MBS 11503 — Pulmonary function tests (spirometry) — useful for surgical risk assessment if resection is contemplated
• Bronchoscopy and endobronchial ultrasound (EBUS) have separate respiratory item numbers

Referral pathway

Clinical situation	Referral
Nodule meeting Fleischner follow-up criteria only	GP manages with repeat CT
Fleischner follow-up CT shows growth or new suspicious features	Respiratory physician (non-urgent)
Solid >8 mm, new spiculation, or haemoptysis	Respiratory physician or thoracic surgery (within 1–2 weeks)
Part-solid with growing solid component	Respiratory MDT via thoracic surgery (urgent)
Known or suspected malignancy	Oncology or respiratory MDT (urgent)

The Cancer Council Australia Lung Cancer Optimal Care Pathway sets a target of tissue diagnosis within 28 days of specialist referral. Most major public hospitals operate a lung MDT integrating respiratory medicine, thoracic surgery, radiation oncology, and palliative care.

Smoking cessation — the highest-yield action

A CT finding of a pulmonary nodule is a powerful teachable moment for cessation counselling. Available supports in Australia:

• Quitline 13 7848 — free telephone coaching, seven days a week; the Quit for You online programme is also available
• Nicotine replacement therapy (NRT) — patches combined with oral NRT (gum, lozenge, or inhaler) more effective than single form; available over the counter
• Varenicline (Champix) — PBS Authority Required Streamlined; the most effective pharmacotherapy, approximately doubling quit rates versus NRT alone; contraindicated in active suicidal ideation — monitor mood
• Bupropion — PBS alternative; lower quit rates than varenicline in direct comparisons

E. Special populations

Older adults (≥75 years)

Comorbidity burden and reduced life expectancy alter the risk-benefit ratio. The Fleischner authors note that clinical judgement should modulate recommendations in older adults — the gain from detecting and treating a small early cancer may be outweighed by procedural risk and shortened life expectancy from competing causes. Shared decision-making with the patient, their family, and if needed a respiratory specialist, is essential before proceeding to biopsy or resection in frail older adults.

Immunocompromised patients

HIV, solid-organ or bone-marrow transplant recipients, and patients on prolonged high-dose corticosteroids have an expanded nodule differential including fungal infection (cryptococcosis, aspergillosis, pulmonary candidiasis), Pneumocystis jirovecii pneumonia (PJP), and lymphoma. The Fleischner guidelines do not apply in this group. New nodules in immunocompromised patients warrant urgent respiratory or infectious diseases referral rather than a watch-and-wait approach.

Patients with a prior or current malignancy

A pulmonary nodule in anyone with a known extrathoracic malignancy — breast, colorectal, melanoma, renal cell, sarcoma — should be regarded as a metastasis until proven otherwise, particularly if multiple nodules are present. A Fleischner watchful approach is usually inappropriate here; refer to the treating oncology team or a respiratory specialist for tissue characterisation.

Aboriginal and Torres Strait Islander peoples

Lung cancer mortality is approximately twice as high in Aboriginal and Torres Strait Islander Australians as in non-Indigenous Australians, with later-stage diagnosis contributing substantially to this gap. Culturally safe communication about the meaning of a nodule finding, the rationale for follow-up imaging, and the importance of returning for scans is critical. Linking with community-controlled health services and Aboriginal health workers supports follow-up adherence. Eligible Aboriginal and Torres Strait Islander Australians who meet the LCSP smoking and age criteria should be offered referral to the programme as a priority.

Young adults (35–50 years)

The Fleischner guidelines apply from age 35, but below 50 years malignancy is uncommon in the absence of smoking or prior cancer. Benign causes (infections, hamartomas, reactive nodes) dominate. Younger people may experience significant anxiety about a CT finding labelled “nodule” even when clinical risk is very low — providing explicit statistical context (“in non-smokers under 50, small solid nodules under 6 mm carry a cancer risk below 1%”) aids decision-making and reduces unnecessary distress.

When to escalate

Contact a respiratory physician or refer through the emergency department if any of the following are present alongside a pulmonary nodule:

• Haemoptysis, new unexplained weight loss, or new breathlessness
• Part-solid nodule with a growing or dominant solid component on any scan
• Solid nodule >8 mm with spiculated margin or upper-lobe location in a smoker
• New or enlarging nodule in a patient with a known malignancy
• PET-CT showing elevated SUV uptake (Deauville/SUV interpretation by nuclear medicine)
• Nodule associated with ipsilateral lymphadenopathy or pleural effusion

Routine Fleischner-protocol follow-up CT does not require a specialist letter and is arranged directly by the GP with rebatable MBS items.

What this article is and is not

This article provides patient-education information about pulmonary nodule classification and management principles based on the Fleischner Society 2017 guidelines and Australian practices current as of 2026. It is not a substitute for assessment by your own GP, who integrates the full radiology report, your smoking history, medical background, and other risk factors to decide the most appropriate plan for you. The tables in this article are management frameworks — your GP’s clinical judgement may appropriately vary from them based on your individual circumstances.

If you have been told you have a pulmonary nodule and are unsure what follow-up you need, book an appointment with your GP to review the radiology report together.

---

Sources cited

• MacMahon et al. Fleischner Society 2017 Guidelines — Radiology
• National Lung Screening Trial (NLST) — NEJM 2011
• NELSON Trial — CT Volume Screening — NEJM 2020
• Lung Foundation Australia — Pulmonary Nodules
• TSANZ — Lung Cancer Screening Statement
• Cancer Council Australia — Lung Cancer Optimal Care Pathway
• RANZCR — Lung Cancer Screening Standards
• eTG — Respiratory: Lung Tumours
• Quit.org.au — Quitting Support